The case for adopting a broader perspective on value in Health Technology Assessment

Priscila Radu, Conchi Biurrun, Meindert Boysen, Melanie Whittington and Chris Skedgel

Whitepaper from Office of Health Economics

Abstract: In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different perspectives. Drawing a panel session at the 2024 European meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), including patient, clinical, and health economics representatives, we argue for a broader perspective on costs and outcomes when assessing the value of new treatments, especially when a health condition or its treatment has significant health or economic impacts beyond the patient. In the context of Health Technology Assessment (HTA), perspective refers to the ‘point…

JEL-codes: I1 (search for similar items in EconPapers)
Date: 2026-03-03
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/the-case-for-adop ... chnology-assessment/ (text/html)
https://www.ohe.org/wp-content/uploads/2026/02/Rad ... ology-Assessment.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:whipap:002528

Access Statistics for this paper

More papers in Whitepaper from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).